Protagonist Therapeutics Inc Revenue Growth Rates (PTGX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Protagonist Therapeutics inc   (NASDAQ: PTGX)
 

PTGX's Revenue Growth by Quarter and Year

Protagonist Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PTGX/growth
https://api.csimarket.com/api/v1/companies/PTGX/fundamentals
https://api.csimarket.com/api/v1/companies/PTGX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PTGX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 274.41
2nd Quarter June 213.48
1st Quarter March 56.37
FY 544.26

PTGXs Annual Revenue
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2025 $ 46.02 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2024 $ 434.43 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2023 $ 60.00 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2022 $ 26.58 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2021 $ 27.36 millions




PTGX Revenue third quarter 2026 Y/Y Growth Comment
Protagonist Therapeutics inc achieved in the third quarter 2026, above Company average Revenue surge of 5726.11% year on year, to $ 274.41 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue growth. While Protagonist Therapeutics Inc ' s Revenue doubling of 5726.11% ranks overall at the positon no. 24 in the third quarter 2026.


PTGX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5726.11 %
2nd Quarter June 3746.49 %
1st Quarter March 99.05 %
FY   -

Financial Statements
Protagonist Therapeutics Inc 's third quarter 2026 Revenue $ 274.41 millions PTGX's Income Statement
Protagonist Therapeutics Inc 's third quarter 2025 Revenue $ 4.71 millions Quarterly PTGX's Income Statement


PTGX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 28.54 %
2nd Quarter June 278.71 %
1st Quarter March 657.66 %
FY (Year on Year)   -


Back to PTGX Growth rate Comparisons >> Back to PTGX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #10
Overall #24

Revenue Y/Y Growth Statistics
High Average Low
3749.17 % 161.14 % -100 %
(Mar 31 2021)   (Sep 30 2019)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #10
Overall #24
Revenue Y/Y Growth Statistics
High Average Low
3749.17 % 161.14 % -100 %
(Mar 31 2021)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Protagonist Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3550.01 % 175.39 % -100 %
(Dec 31 2024)  


PTGX's III. Quarter Q/Q Revenue Comment
Protagonist Therapeutics inc achieved in the III. Quarter 2026 below company average Revenue jump of 28.54% quarter on quarter, to $ 274.41 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -15.14% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Protagonist Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 71.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #28
Overall #71
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #28
Overall #71
Revenue Q/Q Growth Statistics
High Average Low
3550.01 % 175.39 % -100 %
(Dec 31 2024)  


PTGX's III. Quarter Q/Q Revenue Comment
Protagonist Therapeutics inc achieved in the III. Quarter 2026 below company average Revenue jump of 28.54% quarter on quarter, to $ 274.41 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -15.14% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Protagonist Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 71.


Protagonist Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 281.99
Y / Y Revenue Growth (TTM) 34.81 %
Year on Year Revenue Growth Overall Ranking # 3561
Seqeuential Revenue Change (TTM) 280.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 2573


Cumulative Revenue growth Comment
Although Protagonist Therapeutics Inc 's Annual Revenue growth year on year were below company's average 121.5% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.81% year on year, from -64.36% in Mar 31 2026.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2978 to 3561.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 479
Overall # 3561

Revenue TTM Y/Y Growth Statistics
High Average Low
1393.53 %
 121.5 %
-100.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 371
S&P 500 # 2573
Cumulative Revenue growth Comment
Although Protagonist Therapeutics Inc 's Annual Revenue growth year on year were below company's average 121.5% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.81% year on year, from -64.36% in Mar 31 2026.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2978 to 3561.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 479
Overall # 3561

Revenue TTM Y/Y Growth Statistics
High Average Low
1393.53 %
121.5 %
-100.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 371
S&P 500 # 2573




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PTGX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Protagonist Therapeutics inc 5,723.64%$ 5,723.642 millions
Newamsterdam Pharma Company N v 5,406.90%$ 5,406.897 millions
Alector Inc 4,895.89%$ 4,895.890 millions
4d Molecular Therapeutics Inc 4,505.56%$ 4,505.556 millions


About Protagonist Therapeutics Inc Revenue Growth Rates (PTGX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Protagonist Therapeutics Inc (CIK 1377121).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-123620
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Protagonist Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.